JP2018090611A - 食用珪素を含む水溶性溶液の用途方法 - Google Patents
食用珪素を含む水溶性溶液の用途方法 Download PDFInfo
- Publication number
- JP2018090611A JP2018090611A JP2018026629A JP2018026629A JP2018090611A JP 2018090611 A JP2018090611 A JP 2018090611A JP 2018026629 A JP2018026629 A JP 2018026629A JP 2018026629 A JP2018026629 A JP 2018026629A JP 2018090611 A JP2018090611 A JP 2018090611A
- Authority
- JP
- Japan
- Prior art keywords
- water
- silicon
- group
- soluble
- solution containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052710 silicon Inorganic materials 0.000 title claims abstract description 57
- 239000010703 silicon Substances 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 10
- 239000000243 solution Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 26
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 13
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 13
- 241000209094 Oryza Species 0.000 claims description 7
- 235000007164 Oryza sativa Nutrition 0.000 claims description 7
- 239000010903 husk Substances 0.000 claims description 7
- 235000009566 rice Nutrition 0.000 claims description 7
- 230000002550 fecal effect Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000010453 quartz Substances 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000004575 stone Substances 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 16
- 241000124008 Mammalia Species 0.000 abstract description 15
- 235000013361 beverage Nutrition 0.000 abstract description 12
- 230000037396 body weight Effects 0.000 abstract description 12
- 210000000056 organ Anatomy 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000004075 alteration Effects 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000010775 animal oil Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 3
- 239000008158 vegetable oil Substances 0.000 abstract description 3
- 102000010445 Lactoferrin Human genes 0.000 abstract description 2
- 108010063045 Lactoferrin Proteins 0.000 abstract description 2
- 206010067125 Liver injury Diseases 0.000 abstract description 2
- 208000001132 Osteoporosis Diseases 0.000 abstract description 2
- 235000011194 food seasoning agent Nutrition 0.000 abstract description 2
- 206010061989 glomerulosclerosis Diseases 0.000 abstract description 2
- 231100000234 hepatic damage Toxicity 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract description 2
- 229940078795 lactoferrin Drugs 0.000 abstract description 2
- 235000021242 lactoferrin Nutrition 0.000 abstract description 2
- 230000008818 liver damage Effects 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 210000003584 mesangial cell Anatomy 0.000 abstract description 2
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 229920001296 polysiloxane Polymers 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 44
- 235000009200 high fat diet Nutrition 0.000 description 41
- 210000004185 liver Anatomy 0.000 description 17
- 238000012423 maintenance Methods 0.000 description 13
- 239000008399 tap water Substances 0.000 description 11
- 235000020679 tap water Nutrition 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 238000010793 Steam injection (oil industry) Methods 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002470 solid-phase micro-extraction Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- -1 polydimethylsiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Abstract
Description
文献(3)は、特開2010−239903号公報の「植物油及び動物油等食品の長期変質防止製造方法」で、食品の長期変質防止に関する。例えば、水と植物油又は動物油の混合溶液に水溶性珪素を加えた混合溶液を乳濁化し、良質の天然香料に変換するとともに、変質の抑制・腐敗防止を図る。即ち、水溶性珪素の働きで、成分の危険性、変質を抑え、安全な原材料の提供を意図する。また、文献(4)は、特開2010−252774号公報の「血液の中核構成がCuである哺乳動物の加工食品及び製造方法」で、食品の保存期間延長や常温流通に関する。例えば、食品、調味料に水溶性珪素を添加する方法である。
1.使用動物、及び使用条件について、説明する。
2.飼料について、説明する。
3.被験物質について、説明する。
4.実験プロトコールについて、説明する。
6.血液生化学検査について、説明する。
肝臓の病理組織学的検査
剖検の際に採取した肝臓は、常法に従って薄切切片を作製した。肝臓切片はヘマトキシリン−エオジン染色(HE染色)、脂肪染色(オイルレッドO染色)を行った。
7.糞中インドール測定について、説明する。
8.統計学的解析方法について、説明する。
: 発明を実施するための最良の形態であり、前述の条件下におけるデータを、順次説明する。
図表1は、マウスの体重値の推移である。
[図表1]
[図表4−1]
データは、平均値±標準誤差で示した。a,b:異なる英文字間で有意差あり(P<0.05)。
[図表4−2]
[図表5]
[図表6−1]
[図表6−2]
図表7は、SPMEを用いたインドール吸着法を図示したものである。
[図表7]
[図表8]
[図表9]
2 ボイラー
3 配管
4 配管
5 抽出槽
500 スース
5a ポンプ
5b 噴射管
5c 排出口
6 タンク
A 原液
B 炭化籾殻
Claims (6)
- 非ヒト哺乳動物の糞便中インドール濃度を減少させる方法であって、非ヒト哺乳動物に水溶性珪素を含む水溶性溶液を摂取させる工程を含む、前記方法。
- 前記水溶性珪素を含む水溶性溶液が、水晶石を、水中に陥没し、超音波波動を利用して、珪素を生成するか、又は籾殻から高温蒸気を利用して生成するかの何れかの方法で、抽出かつ清澄して生成し、常温下で、保管したものであることを特徴とする、請求項1に記載の方法。
- 前記水溶性珪素を含む水溶性溶液が、水溶液中に、珪素が、6.000〜9.000mg/mLであって、望ましくは、8.000mg/mL溶解しているものであることを特徴とする請求項1又は2に記載の方法。
- 前記非ヒト動物がマウスであることを特徴とする請求項1乃至3のいずれかに記載の方法。
- 水溶性珪素を有効成分として含む、糞便中インドール濃度を減少させるための食品組成物。
- 前記の水溶性珪素が、水晶石を、水中に陥没し、超音波波動を利用して、珪素を生成するか、又は籾殻から高温蒸気を利用して生成するかの何れかの方法で、抽出かつ清澄して生成し、常温下で、保管したものであることを特徴とする請求項5に記載の糞便中インドール濃度を減少させるための食品組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018026629A JP6712076B2 (ja) | 2018-02-19 | 2018-02-19 | 食用珪素を含む水溶性溶液の用途方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018026629A JP6712076B2 (ja) | 2018-02-19 | 2018-02-19 | 食用珪素を含む水溶性溶液の用途方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015182396A Division JP6312144B2 (ja) | 2015-09-16 | 2015-09-16 | 食用珪素を含む水溶性溶液の用途方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018090611A true JP2018090611A (ja) | 2018-06-14 |
JP6712076B2 JP6712076B2 (ja) | 2020-06-17 |
Family
ID=62564318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018026629A Active JP6712076B2 (ja) | 2018-02-19 | 2018-02-19 | 食用珪素を含む水溶性溶液の用途方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6712076B2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7348681B1 (ja) | 2022-04-04 | 2023-09-21 | 株式会社 life park. biz | 水溶性ケイ素溶液の製造方法 |
WO2023190666A1 (ja) * | 2022-03-29 | 2023-10-05 | ケイワート・サイエンス株式会社 | ケイ素化合物水溶液の製造方法 |
WO2023190667A1 (ja) * | 2022-03-29 | 2023-10-05 | ケイワート・サイエンス株式会社 | ケイ素化合物水溶液の製造方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63201081A (ja) * | 1987-02-13 | 1988-08-19 | 執行 祐輔 | 産業廃棄物の有効利用法 |
JPS63202349A (ja) * | 1987-02-19 | 1988-08-22 | Baiotetsuku:Kk | 家畜用飼料 |
JPH06233807A (ja) * | 1993-02-05 | 1994-08-23 | Taiyo Kagaku Co Ltd | 糞便悪臭低減組成物 |
JP2003092998A (ja) * | 2001-09-25 | 2003-04-02 | Harumi Sangyo Kk | 家畜類の養殖用飼料 |
JP2007020481A (ja) * | 2005-07-19 | 2007-02-01 | Mugai Nosha:Kk | 家畜用飼料及びその製造方法 |
JP2011067730A (ja) * | 2009-09-24 | 2011-04-07 | Daiichi Kankyo Aqua Kk | 水処理方法および水処理装置 |
-
2018
- 2018-02-19 JP JP2018026629A patent/JP6712076B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63201081A (ja) * | 1987-02-13 | 1988-08-19 | 執行 祐輔 | 産業廃棄物の有効利用法 |
JPS63202349A (ja) * | 1987-02-19 | 1988-08-22 | Baiotetsuku:Kk | 家畜用飼料 |
JPH06233807A (ja) * | 1993-02-05 | 1994-08-23 | Taiyo Kagaku Co Ltd | 糞便悪臭低減組成物 |
JP2003092998A (ja) * | 2001-09-25 | 2003-04-02 | Harumi Sangyo Kk | 家畜類の養殖用飼料 |
JP2007020481A (ja) * | 2005-07-19 | 2007-02-01 | Mugai Nosha:Kk | 家畜用飼料及びその製造方法 |
JP2011067730A (ja) * | 2009-09-24 | 2011-04-07 | Daiichi Kankyo Aqua Kk | 水処理方法および水処理装置 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023190666A1 (ja) * | 2022-03-29 | 2023-10-05 | ケイワート・サイエンス株式会社 | ケイ素化合物水溶液の製造方法 |
WO2023190667A1 (ja) * | 2022-03-29 | 2023-10-05 | ケイワート・サイエンス株式会社 | ケイ素化合物水溶液の製造方法 |
JP7348681B1 (ja) | 2022-04-04 | 2023-09-21 | 株式会社 life park. biz | 水溶性ケイ素溶液の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP6712076B2 (ja) | 2020-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hursel et al. | Thermogenic ingredients and body weight regulation | |
Huang et al. | 5‐Caffeoylquinic acid decreases diet‐induced obesity in rats by modulating PPARα and LXRα transcription | |
Chen et al. | Cholesterol-lowering nutraceuticals and functional foods | |
Pericleous et al. | Nutrition and pancreatic cancer | |
WO2008017484A1 (en) | Novel agents for the treatment of disorders connected to impaired neurotransmission | |
Heo et al. | Anti-obesity effects of Spirulina maxima in high fat diet induced obese rats via the activation of AMPK pathway and SIRT1 | |
JP2018090611A (ja) | 食用珪素を含む水溶性溶液の用途方法 | |
Nomura et al. | Tea catechins enhance the mRNA expression of uncoupling protein 1 in rat brown adipose tissue | |
Ge et al. | Oxidized pork induces oxidative stress and inflammation by altering gut microbiota in mice | |
WO2010095943A2 (en) | Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning | |
Zhang et al. | Feeding blueberry diets to young rats dose-dependently inhibits bone resorption through suppression of RANKL in stromal cells | |
Kubow et al. | Extract of I rish potatoes (S olanum tuberosum L.) decreases body weight gain and adiposity and improves glucose control in the mouse model of diet‐induced obesity | |
Liu et al. | Flavanol‐rich lychee fruit extract alleviates diet‐induced insulin resistance via suppressing mTOR/SREBP‐1 mediated lipogenesis in liver and restoring insulin signaling in skeletal muscle | |
Song et al. | Black current anthocyanins improve lipid metabolism and modulate gut microbiota in high‐fat diet‐induced obese mice | |
Qin et al. | Cinnamon extract attenuates TNF-α-induced intestinal lipoprotein ApoB48 overproduction by regulating inflammatory, insulin, and lipoprotein pathways in enterocytes | |
US9788560B2 (en) | Supplemental food | |
Sahib et al. | The effects of Morinda citrifolia, Momordica charantia and Centella asiatica extracts on lipoprotein lipase and 3t3‐l1 preadipocytes | |
Foster et al. | The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin‐induced type 2 diabetic rats | |
Diez‐Echave et al. | The beneficial effects of Lippia citriodora extract on diet‐induced obesity in mice are associated with modulation in the gut microbiota composition | |
Zhang et al. | Chlorogenic acid inhibits trimethylamine-N-oxide formation and remodels intestinal microbiota to alleviate liver dysfunction in high L-carnitine feeding mice | |
KR20100088886A (ko) | 카바크롤 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 지방간, 고지혈증 및 당뇨병의 예방및 치료용 조성물 | |
Wang et al. | Oral spermidine targets brown fat and skeletal muscle to mitigate diet‐induced obesity and metabolic disorders | |
Pak‐Dek et al. | Inhibitory effect of Morinda citrifolia L. on lipoprotein lipase activity | |
Ge et al. | Oxidized pork induces hepatic steatosis by impairing thyroid hormone function in mice | |
von Wilmsdorff et al. | The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180402 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190910 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200428 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200514 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6712076 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |